Top Qs
Timeline
Chat
Perspective
Ariadne (drug)
Psychoactive phenethylamine drug From Wikipedia, the free encyclopedia
Remove ads
Ariadne, also known chemically as 4C-D or 4C-DOM, by its developmental code name BL-3912, and by its former tentative brand name Dimoxamine, is a psychoactive drug of the phenethylamine, phenylisobutylamine (α-ethylphenethylamine), and 4C families.[1][2][3][4] It is an analogue of the psychedelic drugs 2C-D and DOM, with 2C-D having no substitution at the α carbon, DOM having an α-methyl group, and Ariadne having an α-ethyl group.[1][2][3][4]
The drug is a serotonin 5-HT2 receptor partial agonist, including of the 5-HT2A receptor.[1] Ariadne is not hallucinogenic in humans, but is psychoactive, with antidepressant and mild stimulant effects.[1][2][3][5] It is thought that the non-psychedelic nature of Ariadne with retained psychoactive effects may be due to reduced activational efficacy at the serotonin 5-HT2A receptor relative to other psychedelics.[1]
Ariadne was first synthesized by Alexander Shulgin in 1968 and its psychoactive effects were discovered by Shulgin in 1969.[5][1][2] It was developed as a potential pharmaceutical drug at Bristol Laboratories, for instance as an antidepressant and for various other uses, and entered clinical trials around 1974.[5][1][4][3] The drug reached phase 3 trials prior to its development being shelved.[5] The development of Ariadne is said to have been discontinued for strategic economic reasons rather than due to issues with effectiveness or safety.[5][1] There has been renewed interest in Ariadne and similar drugs in the 2020s owing to increased interest in psychedelics for treatment of psychiatric disorders.[1]
Remove ads
Use and effects
In his 1991 book PiHKAL, Alexander Shulgin reported human tests of Ariadne at doses of up to 32 mg, finding that it produced "the alert of a psychedelic, with none of the rest of the package".[2] Very little published data exists about the human pharmacology of Ariadne apart from Shulgin's limited testing; unpublished human trials reportedly observed some psychoactive effects, but no hallucinations.[6][1]
In his 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, Shulgin described (R)-Ariadne as increasing mental alertness and producing feelings of well-being at doses of 25 to 50 mg.[3] It was claimed to improve symptoms of manic depression in psychotic individuals at doses of 50 to 100 mg and to improve symptoms of Parkinson's disease at a dosage of 100 mg/day.[3][1] Doses of up to 300 mg resulted in an altered state of consciousness but still no psychedelic effects.[1][3] For comparison, DOM shows psychoactive sub-hallucinogenic effects at doses of 1 to 3 mg and psychedelic effects at doses of more than 3 mg.[1]
Remove ads
Overdose
Ariadne, as the (R)- enantiomer, is active at doses as low as 25 mg and was tested in clinical trials at doses of 50 to 100 mg.[1] Doses as high as 300 mg have been assessed, more than 10 times higher than the minimum reported active dose.[1] No psychedelic effects occurred at this or lower doses, but therapeutic effects were observed.[1]
Interactions
Pharmacology
Summarize
Perspective
Pharmacodynamics
Ariadne is a potent and selective agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[1][8] However, it is less efficacious in activating the serotonin 5-HT2A receptor, including the Gq, G11, and β-arrestin2 signaling pathways, compared to the related drug DOM, and this weaker partial agonism may be responsible for its lack of psychedelic effects.[1][8] In addition to the serotonin 5-HT2 receptors, Ariadne is a lower-affinity agonist of the serotonin 5-HT1 receptors.[1] Ariadne shows essentially no activity at the monoamine transporters.[1]
Ariadne shows a markedly attenuated head-twitch response, a behavioral proxy of psychedelic effects, in animals, although it does still significantly induce a weak head-twitch response.[1][8][9] The drug substitutes for DOM in rodent drug discrimination tests, albeit with dramatically lower potency than DOx drugs like DOM itself, DOET, and DOB.[9] It has also been shown to produce stimulus generalization in rats trained to respond to LSD[6] and MDMA.[10] Ariadne's capacity to fully substitute for MDMA is not shared with DOM and is unusual among psychedelics, but is shared with α-ethyltryptamine (αET).[10][11] In monkeys, Ariadne was found to possibly increase motivation, as it caused monkeys that had stopped running mazes to begin running them again.[2] Ariadne has also been found to be effective in an animal model of Parkinson's disease, where it reversed motor deficits similarly to levodopa.[1]
Serotonin 5-HT2A receptor agonists have been found to increase dopamine levels in the nucleus accumbens and other mesolimbic areas.[1] Non-hallucinogenic serotonin 5-HT2A receptor agonists like Ariadne may produce this effect without causing psychedelic effects.[1] This action may underlie the preliminary observations of effectiveness of Ariadne in the treatment of parkinsonism in animals and humans.[1]
Remove ads
Chemistry
Ariadne, also known as 4-methyl-2,5-dimethoxy-α-ethylphenethylamine, is a substituted phenethylamine and amphetamine derivative.[2][3] It is the analogue of 2,5-dimethoxy-4-methylamphetamine (DOM) in which the α-methyl group has been replaced with an α-ethyl group and is the analogue of 2,5-dimethoxy-4-methylphenethylamine (2C-D) with an ethyl group substituted at the α carbon.[1][2][3]
Ariadne's alternative name 4C-DOM or 4C-D stands for "four-carbon DOM", whereas the name of 2C-D stands for "two-carbon DOM".[1] Another name of Ariadne is α-Et-2C-D, which stands for α-ethyl-2C-D.[9] Racemic Ariadne is additionally known by the former developmental code name BL-3912, while the (R)-enantiomer of Ariadne is known by the former developmental code name BL-3912A.[1][3]
Other related compounds include the 4C derivatives 4C-B (the α-ethyl homologue of 2C-B and DOB) and 4C-T-2 (the α-ethyl homologue of 2C-T-2 and Aleph-2).[2] Unlike Ariadne, 4C-B has been reported to produce pronounced psychedelic effects, although generally milder than those of 2C-B or DOB.[12]
Remove ads
History
Ariadne was first synthesized by Alexander Shulgin in 1968 and he discovered its psychoactive effects in 1969.[5][1][2] Shulgin reported that the drug was tested by Bristol Laboratories as an antidepressant, in an anecdote where he was explaining how human testing is invaluable (compared to animal testing) on drugs that change the state of the mind. He said, "Before they launched into a full multi-clinic study to determine whether it's going to be worth the animal studies or not, every person on the board of directors took it."[4] In The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds (2011), he described it also being evaluated for increasing mental alertness in geriatric individuals, treating Parkinson's disease, and treating psychosis and manic depression.[3][1] The tentative commercial name of Ariadne was Dimoxamine.[3] (R)-Ariadne was said to have completed phase 2 clinical trials and to have reached phase 3 trials, but the actual clinical data were never disclosed and further development was halted due to strategic economic reasons.[5][1]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads